If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Modified HGH fragment 176–191 (anti-obesity drug candidate)
Supply and ordering
Ask sales about AOD9604 availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
AOD9604 is a modified analog of the C-terminal 176-191 fragment of human growth hormone, developed at Monash University in Australia as a lipolytic / anti-obesity research and clinical-development candidate. The molecule is Tyr-hGH(177-191) — HGH residues 177-191 carrying an N-terminal tyrosine (which also supports iodination for tracking studies) — a 16-residue analog that differs from the native 176-191 fragment by a phenylalanine-to-tyrosine change at the N-terminus. AOD9604 retains the lipolytic activity associated with the HGH C-terminal region (the segment hypothesized to drive fat-cell lipolysis through a non-GH-receptor mechanism) while lacking the broader anabolic effects mediated by the full-length HGH molecule's central regions. The molecule advanced through Phase 2 clinical development for obesity but did not achieve regulatory approval; it has since transitioned to research-use and dietary-supplement markets in some jurisdictions. PeptideXpo supplies lyophilized AOD9604 to a ≥99.0% HPLC purity specification with batch-specific COA. The N-terminal tyrosine modification is what distinguishes AOD9604 from the unmodified HGH Fragment 176-191: they are different molecules, and the product offered here is AOD9604. Three standard fill sizes (2, 5, 10 mg) cover typical research and compounding workflows.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Also available as a nasal spray (US stock)
Besides lyophilized vials, AOD9604 is stocked in the US as a ready-to-use nasal spray.
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAAOD9604 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAAOD9604 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAAOD9604 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
AOD9604 was developed at Monash University in Australia and advanced through Phase 2b clinical trials for obesity as a registered drug-development program. The trials produced modest weight-loss signals (smaller than what GLP-1 agonists have since demonstrated), and the program did not achieve regulatory approval as a finished drug. Following discontinuation of the obesity-drug program, AOD9604 transitioned to research-use and to dietary-supplement markets in some jurisdictions, where it is marketed under various brand names. The 'anti-obesity drug candidate' framing reflects the molecule's clinical-development history; buyers should not assume the molecule is an approved drug.
AOD9604 is derived from the C-terminal region of human GH (residues 176-191) but is not a GH receptor agonist, the GH-receptor-binding region of full-length GH is in the central portion of the protein, not the C-terminal fragment. AOD9604's lipolytic activity is hypothesized to act through a separate, non-GH-receptor mechanism. This is the key pharmacological distinction from full-length recombinant HGH: AOD9604 retains the lipolytic effects associated with the C-terminal region of GH but lacks the broader anabolic and IGF-1-stimulating effects mediated by the central GH-receptor-binding region. The downstream consequence is a substantially narrower pharmacological profile than HGH.
Yes. AOD9604 is also stocked as a ready-to-use nasal spray (2 mg, 5 mg, 10 mg) in 10 mL or 20 mL bottles, from 10 bottles of each. These orders ship from our US stock; ask our sales team for details and a quote.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
